Table 3.
Treatment | Percentage |
---|---|
Benralizumab | 60% (3/5) |
Lebrikizumab | 50% (1/2) |
Dupilumab | 0% (0/1) |
Mepolizumab | 50% (1/2) |
Tralokinumab | 100% (1/1) |
Reslizumab | 100% (1/1) |
Tezepelumab | 100% (1/1) |
Table outlining the risk of bias for different studies included in the meta-analysis, all agents had at least 50% of low-risk studies included, except dupilumab